- Home
- JPI vs CCCC Comparison
JPI vs CCCC Comparison
Compare JPI & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JPI
- CCCC
- Stock Information
- Founded
- JPI 2012
- CCCC 2015
- Country
- JPI United States
- CCCC United States
- Employees
- JPI N/A
- CCCC N/A
- Industry
- JPI Finance Companies
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- JPI Finance
- CCCC Health Care
- Exchange
- JPI Nasdaq
- CCCC Nasdaq
- Market Cap
- JPI 278.6M
- CCCC 244.9M
- IPO Year
- JPI N/A
- CCCC 2020
- Fundamental
- Price
- JPI $20.01
- CCCC $3.01
- Analyst Decision
- JPI
- CCCC Buy
- Analyst Count
- JPI 0
- CCCC 5
- Target Price
- JPI N/A
- CCCC $11.60
- AVG Volume (30 Days)
- JPI 54.7K
- CCCC 1.8M
- Earning Date
- JPI 01-01-0001
- CCCC 03-04-2025
- Dividend Yield
- JPI 6.15%
- CCCC N/A
- EPS Growth
- JPI N/A
- CCCC N/A
- EPS
- JPI N/A
- CCCC N/A
- Revenue
- JPI N/A
- CCCC $33,668,000.00
- Revenue This Year
- JPI N/A
- CCCC $75.59
- Revenue Next Year
- JPI N/A
- CCCC N/A
- P/E Ratio
- JPI N/A
- CCCC N/A
- Revenue Growth
- JPI N/A
- CCCC 65.45
- 52 Week Low
- JPI $16.02
- CCCC $2.79
- 52 Week High
- JPI $19.12
- CCCC $11.88
- Technical
- Relative Strength Index (RSI)
- JPI 41.81
- CCCC 33.55
- Support Level
- JPI $19.95
- CCCC $2.79
- Resistance Level
- JPI $20.38
- CCCC $3.38
- Average True Range (ATR)
- JPI 0.23
- CCCC 0.20
- MACD
- JPI -0.03
- CCCC -0.03
- Stochastic Oscillator
- JPI 8.87
- CCCC 23.66
About JPI Nuveen Preferred and Income Term Fund of Beneficial Interest
Nuveen Preferred and Income Term Fund is a closed-end management investment company. Its investment objective is to provide a high level of current income and total return. The company's products include mutual funds, closed-end funds, Exchange-traded funds, Multi-asset model portfolios, and others.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.